胆汁淤积性肝病相关并发症的处理*

doi:10.3969/j.issn.1672-5069.2019.06.041

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (6): 938-940.doi: 10.3969/j.issn.1672-5069.2019.06.041

胆汁淤积性肝病相关并发症的处理^*

丁雯瑾, 范建高

200092上海市交通大学医学院附属新华医院消化内科

收稿日期:2019-08-02 出版日期:2019-11-13 发布日期:2019-11-13
通讯作者: 范建高,E-mail：fanjiangao@xinhuamed.com.cn
作者简介:丁雯瑾,女,38岁,医学博士,悉尼大学访问学者,副主任医师,硕士生导师。主要从事慢性肝病防治研究。E-mail: dingwenjin@xinhuamed.com.cn
基金资助:
*国家自然科学基金资助项目（编号：81400610/ 81873565）; 上海交通大学医工交叉研究基金资助项目（YG2016MS72）

Management of complications associated with cholestatic liver disease

Ding Wenjin, Fan Jiangao.

Department of Gastroenterology,Xinhua Hospital,Affiliated to JiaoTong University School of Medicine,Shanghai 200092,China

Received:2019-08-02 Online:2019-11-13 Published:2019-11-13

摘要/Abstract

关键词: 胆汁淤积性肝病, 并发症, 处理

Key words: Cholestatic liver disease, Complication, Management

丁雯瑾, 范建高. 胆汁淤积性肝病相关并发症的处理^*[J]. 实用肝脏病杂志, 2019, 22(6): 938-940.

Ding Wenjin, Fan Jiangao.. Management of complications associated with cholestatic liver disease[J]. Journal of Practical Hepatology, 2019, 22(6): 938-940.

[1] AI-Dury S,Wahlstr<inline-graphic xlink:href="-22-6-938/img_1.png"/>m A,Wahlin S,et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep,2018,8:6658.
[2] Beuers U,Kremer AE,Bolier R,et al.Pruritus in cholestasis:facts and fiction. Hepatology,2014,60(1):399-407.
[3] Onofrio FQ,Hirschfield GM,Gulamhusein AF.A practical review of primary biliary cholangitis for the gastroenterologist. Gastroenterol Hepatol,2019,15(3):145-154.
[4] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015年). 实用肝脏病杂志. 2016,19(6):771-781.
[5] Jin XY,Khan TM.Quality of life among patients suffering from cholestatic liver disease-inducedpruritus:A systematic review. J Formos Med Assoc,2016,115(9):689-702.
[6] Ataei S,Kord L,Larki A,et al.Comparison of sertraline with rifampin in the treatment of cholestatic pruritus:A randomized clinical trial. Rev Recent Clin Trials,2019,[Epub ahead of print].
[7] De Vloo C,Nevens F.Cholestatic pruritus:an update. Acta Gastroenterol Belg,2019,82(1):75-82.
[8] Hegade VS,Krawczyk M,Kremer AE,et al.The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus:a multicentre European study. Aliment Pharmacol Ther,2016,43(2):294-302.
[9] Poupon RE,Chrétien Y,Chazouillères O,et al.Quality of life in patients with primary biliary cirrhosis. Hepatology,2014,40:489-494.
[10] Jopson L,Jones DEJ.Fatigue in primary biliary cirrhosis:prevalence,pathogenesis and management. Dig Dis,2015,33:109-114.
[11] 陆伦根. 胆汁淤积性肝病肝外并发症诊治研究进展. 中华肝脏病杂志,2016,24(8):561-564.
[12] Silveira MG,Gossard AA,Stahler AC,et al.A randomized,placebo-controlled clinical trial of efficacy and safety:Modafinil in the treatment of fatigue in patients with primary biliary cirrhosis. Am J Ther,2017,24(2):e167-e176.
[13] Khanna A,Jopson L,Howel D,et al.Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis:A phase 2 randomized controlled trial. Hepatology,2018,[Epub ahead of print].
[14] Lee JY,Danford CJ,Trivedi HD,et al.Treatment of fatigue in primary biliary cholangitis:A systematic review and Meta-analysis. Dig Dis Sci,2019,[Epub ahead of print].
[15] Gossard AA,Lindor KD.Current and promising therapy for primary biliary cholangitis. Expert Opin Pharmacother,2019,20(9):1161-1167.
[16] Guanabens N,Parés A.Osteoporosis in chronic liver disease. Liver Int,2018,38(5):776-785.
[17] Guanabens N,Ruiz-Gaspa S,Gifre L,et al.Sclerostin expression in bile ducts of patients with chronic cholestasis may influence the bone disease in primary biliary cirrhosis. J Bone Miner Res,2016,31:1725-1733.
[18] Schmidt T,Schwinge D,Rolvien T,et al.Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. J Hepatol,2019,70(5):941-953.
[19] Danford CJ,Trivedi HD,Papamichael K,et al.Osteoporosis in primary biliary cholangitis. World J Gastroenterol,2018,24(31):3513-3520.
[20] Khosla S,Hofbauer LC.Osteoporosis treatment:recent developments and ongoing challenges. Lancet Diabetes Endocrinol,2017,5:898-907.
[21] Danford CJ,Ezaz G,Trivedi HD,et al.The pharmacologic management of osteoporosis in primary biliary cholangitis:A systematic review and Meta-analysis.J Clin Densitom,2019,[Epub ahead of print].
[22] 陆伦根. 胆汁淤积性肝病的正确认识与科学管理. 实用肝脏病杂志,2019,22(5):754-757.

胆汁淤积性肝病相关并发症的处理^*

Management of complications associated with cholestatic liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黎秋曦, 贾健锋, 黄锐. 经皮微波消融术治疗的肝海绵状血管瘤患者血红蛋白尿发生及其处理*[J]. 实用肝脏病杂志, 2019, 22(5): 732-735.
[2]	陆伦根. 胆汁淤积性肝病的正确认识与科学管理[J]. 实用肝脏病杂志, 2019, 22(5): 754-757.
[3]	洪佳, 吴晓宁, 尤红. 胆汁淤积性肝病的规范化诊断[J]. 实用肝脏病杂志, 2019, 22(5): 758-760.
[4]	祁莉娜, 颜梅, 郭建琴. 腹腔镜下肝囊肿开窗术与超声引导下穿刺介入治疗单纯性肝囊肿患者疗效对比研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 581-584.
[5]	卢西梅, 康燕飞, 宋智勇, 朱乔. 彩色多普勒超声检查诊断肝移植术后胆道并发症价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 589-592.
[6]	马信奎, 刘勇, 张伟. 经皮经肝胆道镜硬镜碎石术治疗肝内胆管结石患者临床疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 593-596.
[7]	杨蕊旭, 范建高. 欧洲失代偿期肝硬化并发症管理指南简介[J]. 实用肝脏病杂志, 2018, 21(4): 496-501.
[8]	杨凯奇, 陈世耀. 特发性门静脉高压症预后及其影响因素*[J]. 实用肝脏病杂志, 2018, 21(3): 332-335.
[9]	俞阳, 陈中皓, 廖作富, 李军. 腹腔镜胆囊切除术治疗酒精性肝硬化合并胆囊结石患者临床疗效及其并发症相关危险因素分析[J]. 实用肝脏病杂志, 2018, 21(3): 364-367.
[10]	陈杰, 范作鹏, 梁珊, 聂巍, 仇丽霞, 杨海霞, 林伟, 刘义荣, 张晶, 胡中杰. 合并慢性胆汁淤积性肝病对慢性药物性肝损害患者临床表现及对治疗应答的影响*[J]. 实用肝脏病杂志, 2017, 20(6): 720-723.
[11]	伍强, 李光耀, 皮儒先, 王伟, 陈平. LLLR与OLLR治疗左外叶肝细胞癌临床效果及远期生存率比较[J]. 实用肝脏病杂志, 2017, 20(4): 451-454.
[12]	刘艳，赵卫峰，甘建和，浦永兰，王杰，范斌，李仲华. Fibrotouch联合FIB-4指数对肝硬化患者发生并发症的预测价值[J]. 实用肝脏病杂志, 2017, 20(2): 175-178.
[13]	江现强，俞渊，陆世锋. 腹腔镜肝叶切除术常见并发症的危险因素分析及临床处理[J]. 实用肝脏病杂志, 2017, 20(2): 215-218.
[14]	施漪雯，尤红. 重视胆汁淤积性肝病的诊断和药物治疗[J]. 实用肝脏病杂志, 2016, 19(6): 641-643.
[15]	沈斐斐，陆伦根. 胆汁淤积性肝病的病因[J]. 实用肝脏病杂志, 2016, 19(6): 644-646.